- βPancreatitis was rare β only 4 out of 222 pancreatitis patients were taking Mounjaro (1.8%)
- βAll cases in Mounjaro users were mild, with no intensive care admissions or serious complications
- βMost cases had identifiable alternative causes like gallstones or alcohol, not Mounjaro alone
| Journal | Cureus |
| Year | 2025 |
| PMID | 41409973 |
What Was This Study About?
Researchers at a UK hospital reviewed one year of patient records to understand how often people taking tirzepatide (Mounjaro) developed pancreatitis β an inflammation of the pancreas that can cause significant abdominal pain.
What Did They Find?
Out of 222 patients admitted to hospital with pancreatitis over 12 months, only 4 patients (1.8%) were taking Mounjaro. All four cases were:
- Female with a BMI in the overweight-to-obese range
- Experiencing their first-ever episode of acute pancreatitis
- Mild cases β none required intensive care, and there were no serious complications
Were There Other Explanations?
Importantly, most cases had other likely causes:
- Two patients had gallstones (a known cause of pancreatitis)
- One reported alcohol use
- Only one had no other clear cause identified
Researchers noted that rapid weight loss β which Mounjaro is known to cause β can itself increase the risk of gallstones, which may then trigger pancreatitis.
How Does This Compare to Clinical Trials?
In large US FDA-reviewed trials, pancreatitis occurred in roughly 0.32β0.39% of Mounjaro users, which was similar to the placebo (non-drug) group. This UK audit's findings are broadly consistent with that low risk level.
What Should You Do If You Take Mounjaro?
The researchers advise that doctors stay alert β particularly during the early months of treatment when weight loss is fastest and gallstone risk may be higher.
Seek medical attention promptly if you experience:
- Severe or persistent abdominal pain
- Pain that radiates to your back
- Nausea or vomiting alongside abdominal pain
Could Pancreatitis Be Prevented?
The study mentions a potential preventive option: a medication called ursodeoxycholic acid, which may help prevent gallstones in people at high risk during rapid weight loss. However, this is not yet standard practice and needs further research.
What Are the Limitations?
This was a small, single-hospital study. We don't know the total number of patients on Mounjaro in that area, making it hard to calculate a precise risk rate. Larger, multi-centre studies are needed.
Bottom Line
Pancreatitis in Mounjaro users appears to be uncommon and typically mild, with other factors like gallstones often playing a role. Don't stop your medication without speaking to your doctor, but do report any new abdominal symptoms promptly.